Eikon Therapeutics closed at $6.39 on Nov 4, up 15.14%, 60.7% below its highest close since Feb 5. Volume of 659.5K shares was 1.22× its 20-day average (close to normal).
Split-adjusted performance: -14.9% over one month, -35.9% over six months.
Short interest was 6.4M shares at the Oct 15 settlement, up 1.2% from the prior report (20.4% of float, 11.7 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| EIKNEikon Therapeutics | $6.39 | +15.14% | −35.9% | — | — | — | $346.1M | |
| FENCFennec Pharmaceuticals | $10.35 | −3.27% | +44.2% | +85.2% | 11.0% | — | $362.9M | Compare |
| SRZNSurrozen | $31.65 | +5.08% | −7.3% | +408.6% | 640.8% | — | $372.0M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
| KYTXKyverna Therapeutics | $5.16 | 0.00% | −45.5% | — | — | — | $319.1M | Compare |
| SCTXScribe Therapeutics | $16.78 | +3.58% | — | — | — | — | $317.7M | Compare |
| AGENAgenus | $6.97 | +4.50% | +79.2% | +34.4% | −1.7% | 3.4 | $314.8M | Compare |
| CCCCC4 Therapeutics | $3.12 | −2.80% | +6.5% | +2.8% | −355.9% | — | $383.8M | Compare |
| ZURAZura Bio Limited | $4.02 | +0.75% | −17.8% | — | — | — | $387.2M | Compare |
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
